IL-17RE Antibody (934832) [Unconjugated]

HEK293 human embryonic kidney cell line transfected with either (A) human IL-17 RE or (B) human IL-17 RA and eGFP was stained with Mouse Anti-Human IL-17 RE Monoclonal Antibody (Catalog # MAB8358) followed by Allophycocyanin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0101B). Quadrant markers were set based on control antibody staining (Catalog # MAB002). View our protocol for Staining Membrane-associated Proteins.

• Reactivity: Hu
• Applications: Flow, B/N, CyTOF-ready
• Clone: 934832
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

IL-17RE Antibody (934832) [Unconjugated] Summary

• Immunogen: Chinese hamster ovary cell line CHO-derived recombinant human IL-17 RE
  Met1-His454
  Accession # Q8NFR9
• Specificity: Detects human IL-17 RE in direct ELISAs.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: IL17RE
• Purity Statement: Protein A or G purified from hybridoma culture supernatant
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Blockade of Receptor-ligand Interaction
  • CyTOF-ready
  • Flow Cytometry 0.25 ug/10^6 cells

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for IL-17RE Antibody (934832) [Unconjugated]

• IL-17 RE
• IL-17 receptor E
• IL17RE
• IL-17RE
• Il25r
• interleukin 17 receptor E

Background

Interleukin-17 Receptor E (IL-17 RE) is an approximately 70 kDa (predicted) transmembrane protein in the family of IL-17 receptors. IL-17 RE is required for mediating the pro-inflammatory and homeostatic actions of IL-17C in the skin and mucosa (1, 2). Mature human IL-17 RE consists of a 431 amino acid (aa) extracellular domain, a 21 aa transmembrane segment, and a 192 aa cytoplasmic domain with one SEFIR/TIR domain (3). Within aa 115-454, human IL-17 RE shares 79% aa sequence identity with mouse and rat IL-17 RE. Alternative splicing of human IL-17 RE generates additional isoforms with a 116 aa N-terminal deletion and/or substitution and truncation in the ECD following aa 268 or aa 433. IL-17 RE is expressed on keratinocytes, mucosal epithelial cells, Th17 cells, and gamma /δ T cells (4, 5). It associates with the widely expressed IL-17 RA to form a heterodimeric receptor for IL-17C (4-6). IL-17C binds to IL-17 RE with high affinity and to IL-17 RA with low affinity (4, 5). IL-17C expression is induced by inflammatory stimulation in colon and airway epithelial cells, keratinocytes, CD4⁺ T cells, macrophages, and dendritic cells (4, 6, 7-9). It is up-regulated in various chronic inflammatory diseases including psoriasis, cystic fibrosis, and chronic obstructive pulmonary disease (COPD) (7, 8, 10). IL-17 RE is reciprocally down-regulated in psoriatic lesions (10). The interaction of IL-17C with IL-17 RE promotes mucosal immunity through the induction of anti-bacterial peptides and pro-inflammatory cytokines and chemokines (4, 6, 8, 9). IL-17C action supports the integrity of the colon epithelium following infection induced damage (4, 6, 11) but also contributes to psoriatic skin thickening and the progression of arthritis (4, 8, 9). IL-17C is additionally up-regulated in Th17 cell dependent autoimmunity (5). In this setting, it exacerbates disease severity by inducing Th17 cell production of IL-17A, IL-17F, IL-22, CCR6, and CCL20 (5). The up-regulation of IL-17 RE in hepatocellular carcinoma is associated with poor prognosis (12).

1. Pappu, R. et al. (2012) Trends Immunol. 33:343.
2. Rubino, S.J. et al. (2012) Trends Immunol. 33:112.
3. Li, T.S. et al. (2006) Cell. Signal. 18:1287.
4. Ramirez-Carrozzi, V. et al. (2011) Nat. Immunol. 12:1159.
5. Chang, S.H. et al. (2011) Immunity 35:611.
6. Song, X. et al. (2011) Nat. Immunol. 12:1151.
7. Pfeifer, P. et al. (2013) Am. J. Respir. Cell Mol. Biol. 48:415.
8. Johnston, A. et al. (2013) J. Immunol. 190:2252.
9. Yamaguchi, Y. et al. (2007) J. Immunol. 179:7128.
10. Johansen, C. et al. (2009) Br. J. Dermatol. 160:319.
11. Reynolds, J.M. et al. (2012) J. Immunol. 189:4226.
12. Liao, R. et al. (2013) J. Exp. Clin. Cancer Res. 32:3.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: IL17RE
• Uniprot:
  • Q8NFR9()